The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

Article Abstract:

Celecoxib (Celebrex) may reduce the number of polyps in people with familial adenomatous polyposis. Familial adenomatous polyposis is a hereditary disease characterized by intestinal polyps and is considered a precursor of colorectal cancer. Researchers randomly assigned 77 patients with familial adenomatous polyposis to take 100 milligrams of celecoxib every day for six months, 400 milligrams, or a placebo. Those who took 400 milligrams has 28% fewer intestinal polys after six months than those who took a placebo. Those who took 100 milligrams had 12% fewer intestinal polyps.

Evaluation, Product/Service Evaluation, Prevention, Intestinal polyps, Celebrex (Medication), Polyposis, Familial, Familial polyposis

---

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

Article Abstract:

A case study was conducted on all potentially serious cardiovascular events among 2035 patients with a history of colorectal neoplasia who are enrolled in a trial comparing two doses of celecoxib with placebo for the prevention of colorectal adenomas. Celecoxib use was associated with a dose-related increase in the composite endpoint of death from cardiovascular causes, myocardial infarction, stroke, or heart failure thus providing further evidence that the use of COX-2 inhibitors may increase the risk of serious cardiovascular events.

United States, Science & research, Research, Cardiovascular diseases, Risk factors, COX-2 inhibitors, Dosage and administration

---

Antibiotic Treatment of Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue

Article Abstract:

Stomach cancer of the mucosa-associated lymphoid tissue (MALT) is related to Helicobacter pylori infection, depends on it for growth, and seems to respond well to antibiotics, including complete remission in some cases. Of 24 H. pylori positive patients with gastric MALT lymphoma, treated with antibioitics and followed up for a period of between 18 and 70 months, 14 (50%) had complete remission, eight (29%) had partial remission (with eventual failure in four of the eight), and 10 had no response to treatment. (Changing classifications accounts for percentage over 100%) Treatment was not effective in patients without H. pylori.

Statistical Data Included, Causes of, Physiological aspects, Lymphomas, Helicobacter pylori, Lymphoid tissue, Stomach cancer

Similar abstracts:

• Abstracts: Factors associated with the intent of firearm-related injuries in pediatric trauma patients. Childhood Head Injuries: Accidental or Inflicted?
• Abstracts: Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders: a study of four cases
• Abstracts: Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. Exercise -- toning up the endothelium?
• Abstracts: Predictive factors for neonatal morbidity in neonates with an umbilical arterial cord pH less than 7.00. Can antenatal clinical and biochemical markers predict the development of severe preeclampsia?
• Abstracts: The role of diacylglycerol as a modulator of oxytocin-stimulated phasic contractions in myometrium from pregnant and nonpregnant rats

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.